Study of efficacy of intravitreal triamcinolone acetonide (IVTA) for the treatment of refractory diabetic macular edema (DME) in type 2 diabetes mellitus patients

Abstract

Aim:\xa0To study the efficacy of intravitreal triamcinolone acetonide (IVTA) for the treatment of refractory diabetic macular edema (DME) in type 2 diabetes mellitus patients.\nMaterials and Methods:\xa0A prospective, interventional, non-comparative case series. There were 13 eyes of 13 patients with refractory DME. An intravitreal injection of triamcinolone acetonide at the dose of 4 mg in 0.1 ml was administered. Best corrected visual acuity was measured at each examination. The amount of hard exudates deposition in the macula was subjectively evaluated using colour fundus photographs. Central macular thickness (CMT) was measured, on OCT.\nResults:\xa013 patients completed 6 months or more of follow up and were included in the study. Sex distribution in the study was 12 (92.40%) males and 1 female (7.60%). There was significant improvement in the visual acuity, 2.42 ± 1 (mean ± SD) (p\nConclusions: Intravitreal injection of 4 mg of triamcinolone acetonide may be beneficial for improving visual acuity in type 2 diabetes patients which have refractory diabetic macular edema.\n\nKeywords: Diabetic Macular Edema (DME), Intra Vitreal Triamcinolone Acetonide (IVTA).